Bristol-Myers Squibb (NYSE:BMY) Vs. JNJ, PFE, LLY, ABBV, MRK, ZTS, RPRX, HZNP, JAZZ, and PRGO
Should you be buying Bristol-Myers Squibb stock or one of its competitors? The main competitors of Bristol-Myers Squibb include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly and (LLY), AbbVie (ABBV), Merck & Co., Inc. (MRK), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), and Perrigo (PRGO). These companies are all part of the "pharmaceuticals" industry.
Bristol-Myers Squibb vs.
Johnson & Johnson (NYSE:JNJ) and Bristol-Myers Squibb (NYSE:BMY) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.
Johnson & Johnson has higher revenue and earnings than Bristol-Myers Squibb. Johnson & Johnson is trading at a lower price-to-earnings ratio than Bristol-Myers Squibb, indicating that it is currently the more affordable of the two stocks.
Johnson & Johnson presently has a consensus target price of $191.33, suggesting a potential upside of 7.44%. Bristol-Myers Squibb has a consensus target price of $71.33, suggesting a potential downside of 7.25%. Given Johnson & Johnson's stronger consensus rating and higher probable upside, equities research analysts plainly believe Johnson & Johnson is more favorable than Bristol-Myers Squibb.
Johnson & Johnson has a net margin of 20.90% compared to Bristol-Myers Squibb's net margin of 13.31%. Bristol-Myers Squibb's return on equity of 48.37% beat Johnson & Johnson's return on equity.
68.8% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 73.1% of Bristol-Myers Squibb shares are owned by institutional investors. 0.4% of Johnson & Johnson shares are owned by company insiders. Comparatively, 0.1% of Bristol-Myers Squibb shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, Bristol-Myers Squibb had 12 more articles in the media than Johnson & Johnson. MarketBeat recorded 25 mentions for Bristol-Myers Squibb and 13 mentions for Johnson & Johnson. Johnson & Johnson's average media sentiment score of 0.33 beat Bristol-Myers Squibb's score of 0.05 indicating that Johnson & Johnson is being referred to more favorably in the media.
Bristol-Myers Squibb received 11 more outperform votes than Johnson & Johnson when rated by MarketBeat users. Likewise, 68.55% of users gave Bristol-Myers Squibb an outperform vote while only 65.88% of users gave Johnson & Johnson an outperform vote.
Johnson & Johnson has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500. Comparatively, Bristol-Myers Squibb has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500.
Johnson & Johnson pays an annual dividend of $4.24 per share and has a dividend yield of 2.4%. Bristol-Myers Squibb pays an annual dividend of $2.16 per share and has a dividend yield of 2.8%. Johnson & Johnson pays out 57.1% of its earnings in the form of a dividend. Bristol-Myers Squibb pays out 76.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Johnson & Johnson has increased its dividend for 61 consecutive years and Bristol-Myers Squibb has increased its dividend for 16 consecutive years.
Summary
Johnson & Johnson beats Bristol-Myers Squibb on 12 of the 20 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bristol-Myers Squibb (NYSE:BMY) vs. Its Competitors
Bristol-Myers Squibb Competitors List
